Welcome to our dedicated page for BillionToOne SEC filings (Ticker: BLLN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
BillionToOne, Inc. filings document the regulatory record for a public molecular diagnostics company commercializing QCT-based prenatal and oncology testing. Recent Form 8-K disclosures furnish operating results, financial guidance, Regulation FD presentation materials and executive compensation arrangements, including the company’s annual incentive plan and equity-based payment provisions.
Proxy materials describe annual meeting mechanics, stockholder voting matters, board governance and related governance disclosures. Together, the filings address the company’s clinical testing revenue categories, Class A common stock compensation framework, furnished earnings materials and governance matters relevant to its Nasdaq-listed operating-company status.
NeoTribe-affiliated funds and entities, each a 10% owner of BillionToOne, Inc., reported internal restructuring transactions in Class A Common Stock. On May 11, 2026, they executed J-code “other” transactions totaling 465,607 shares, classified as pro-rata, in-kind distributions to partners and members for no additional consideration.
These moves shifted shares among related funds and their investors at a stated price of $0.00 per share, changing how holdings are allocated between direct and indirect ownership but not reflecting open-market purchases or sales of BLLN stock.
BillionToOne director and ten percent owner Krishna Kittu Kolluri reported multiple internal restructuring transactions involving Class A Common Stock of BillionToOne, Inc. All 16 entries use transaction code J, reflecting other acquisitions or dispositions rather than open-market buys or sells.
The footnotes explain that NeoTribe investment funds, special purpose vehicles, and related entities made pro-rata, in-kind distributions of shares to partners, members, assignees, and family trusts for no additional consideration. The reported securities are held indirectly through these entities, and Kolluri generally disclaims beneficial ownership beyond his pecuniary interest.
BillionToOne, Inc. reported a sharp turnaround in Q1 2026, moving to profitability as revenue and test volumes scaled rapidly. Revenue rose to $108.4 million from $59.0 million a year earlier, driven by higher volumes and better pricing, especially in prenatal testing. Net income reached $18.0 million versus a prior-year loss of $4.0 million, and gross margin expanded to 73% from 64%.
Prenatal testing generated $96.5 million of revenue, oncology tests contributed $10.7 million, and clinical trial and other services added $1.1 million. Delivered and billable test volume grew to about 188,000 from 131,000. Operating cash flow improved to $15.4 million, while cash and cash equivalents increased to $537.5 million, supported by a new $30.0 million term loan tranche that lifted the fair value of long‑term debt to $90.0 million.
BillionToOne, Inc. reported sharply higher first quarter 2026 results, with total revenue of $108.4 million, up 84% from the first quarter of 2025. Growth was driven by a 44% increase in tests delivered and a 28% rise in overall average selling price.
Prenatal testing revenue reached $96.5 million, up 72%, while oncology testing revenue was $10.7 million, more than four times the prior year. Gross margin improved to 73% from 64%, supporting income from operations of $17.8 million versus a loss a year earlier. Net income was $17.97 million, or $0.34 per diluted share. The company raised its 2026 revenue outlook to a range of $450 million to $465 million, implying 48% to 52% growth over 2025, and expects to maintain profitability near current levels while continuing to invest.
BillionToOne, Inc. is asking stockholders to vote at its 2026 virtual annual meeting on June 10, 2026. The main items are electing two Class I directors, Oguzhan Atay and Akshay Rai, to serve until 2029, and ratifying PricewaterhouseCoopers LLP as independent auditor for 2026.
The company has 45,994,764 shares of common stock outstanding as of April 17, 2026, with Class A shares carrying one vote and Class B shares carrying 15 votes. The proxy also details board structure, director and executive compensation, committee responsibilities, and governance policies, including a code of conduct and board independence.
BillionToOne, Inc. describes how its proprietary single-molecule next-generation sequencing (smNGS) platform underpins a growing portfolio of prenatal and oncology diagnostics. The UNITY prenatal line screens for recessive single-gene disorders, aneuploidies, and fetal antigens from a single maternal blood draw, aiming to become a new standard of care.
In oncology, Northstar Select and Northstar Response offer ultrasensitive liquid biopsies for therapy selection and real-time treatment monitoring across solid tumors, with clinical studies supporting superior mutation detection and early response assessment. BillionToOne also highlights a global Johnson & Johnson partnership around HDFN companion diagnostics, over one million tests processed, heavy investment in AI-enabled workflows, and a rapidly expanding U.S. sales force to drive further adoption and reimbursement gains.
BillionToOne, Inc. reported very strong results for the fourth quarter and full year 2025 and introduced an executive and employee bonus plan. Fourth quarter revenue was $96.1 million, up 113% from $45.1 million a year earlier, driven by 47% more tests delivered and a 47% higher overall average selling price.
Gross margin in the quarter improved to 71% from 57%, helping swing to operating income of $10.3 million from an $11.7 million loss. Full year 2025 revenue doubled to $305.1 million, with operating income of $16.0 million versus a $47.1 million loss in 2024, and net income attributable to common stockholders of $2.9 million. The company ended 2025 with $496.0 million in cash and cash equivalents.
The company raised its 2026 revenue outlook to a range of $430 million to $445 million, implying 41% to 46% growth over 2025, and expects positive GAAP operating income for 2026. Separately, the board adopted the BillionToOne Annual Incentive Plan, a performance-based bonus program for executive officers and selected employees, with bonuses payable in cash or fully vested Class A common stock.
BillionToOne, Inc. investor David Tsao has disclosed a 6.9% beneficial ownership stake in the company’s Class A common stock as of 12/31/2025. This totals 3,035,767 shares over which he has sole voting and dispositive power.
The position consists of 1,000 Class A shares, 2,325,108 Class B shares that are convertible into Class A, and 709,659 Class A shares underlying stock options exercisable within 60 days. An additional 431,892 option shares that are not exercisable within 60 days are specifically excluded from this calculation.
Oguzhan Atay filed a Schedule 13G reporting a significant ownership position in BillionToOne, Inc. He is deemed to beneficially own 3,206,861 shares of Class A common stock, representing 7.3% of the class. This total includes Class B shares convertible into Class A, stock options exercisable within 60 days, and shares held by his spouse, over which he disclaims beneficial ownership.